ACP issues new colorectal screening guidance

Average-risk adults should be screened for colorectal cancer starting at age 50 years, and high-risk adults at age 40 years or 10 years younger than the age at diagnosis of the youngest affected relative, according to a new guidance statement from the American College of Physicians (ACP) (Ann Intern Med. 2012;156:378-386).


The new document calls for clinicians to perform individualized risk assessments for colorectal cancer in all adults. Risk factors include increasing age; race (African Americans have the highest incidence and mortality rates for colorectal cancer in the United States); personal history of polyps, inflammatory bowel disease, or colorectal cancer; and family history of colorectal cancer.


Once a patient is assessed, the clinician should follow the above-stated age guidelines for screening initiation. The ACP also advises discontinuing screening in adults older than 75 years and in adults with a life expectancy of less than 10 years.


Average-risk patients should be screened for colorectal cancer using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy, and high-risk patients should undergo optical colonoscopy. However, counsels the ACP, tests should be selected based on the benefits and harms as well as availability, and also should be based on patient preferences.


When choosing a stool-based test, clinicians may not want to use fecal DNA tests based on a recent white paper issued by the Agency for Healthcare Research and Quality (AHRQ). After conducting a review, the agency determined that insufficient evidence exists to support using fecal DNA tests to screen adults at average risk of colorectal cancer. AHRQ calls for further research on the effectiveness of fecal DNA testing compared with other stool-based screening tests (AHRQ Publication No. 12-EHC022-EF). ONA

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in In the News

Fear of lymphedema after sentinel lymph node biopsy greater than risk

Fear of lymphedema after sentinel lymph node biopsy ...

Despite the low risk of lymphedema after sentinel lymph node biopsy, most women worry about this complication and practice risk-reducing behaviors to avoid it.

25-year survival after prostate radiation matches prostatectomy

25-year survival after prostate radiation matches prostatectomy

Late recurrence of prostate cancer is rare if PSA is less than 0.2 ng/mL, the surgical PSA definition of cancer control, 15 years after treatment with radiation therapy.

Diet can thwart prostate 
cancer progression

Diet can thwart prostate 
cancer progression

Men with early-stage prostate cancer may be able to inhibit tumor growth and progression by following a high-fiber diet.